BioSpace News Archive

Canadian health and wellness brand, Revelox plans to expand their selling model after a successful round of meetings at the historic virtual ECRM conference.

Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the first quarter ended March 31, 2020 . “We are exploring strategic opportunities for our anti-CTLA-4 antibody, which shows strong comparative results in pre-clinical cancer tr

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO is now a stand-alone public company with plans to list shares on Nasdaq MIRAMAR, Fla., June 26, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology is pleased to announce its inaugural shareholder meeting as a public stand-alone company. The company will introduce the management team and its world class board

IsoPlexis, the leader in single-cell proteomics, today announced that Peter Siesel has joined the company as Chief Commercial Officer. In this role, Mr. Siesel will continue to advance IsoPlexis’ commercialization and market expansion efforts by leading global sales and customer support, as well as expansion into key regions for ma

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN), today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, MD, PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during the Hotline and Innovation Session. REDUCER-I is a multi-center, international, three-arm prospective and retrospective observational study enrolling up to 4

Celltex, a Houston, Texas-based biotechnology company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). This press release features multimedia. View

BioKansas has received a grant from Burroughs Wellcome Fund to develop a bioscience industry immersion program for PhD students. The new program aims to broaden area students’ understanding of career options, expand their professional networks, provide awareness of area job opportunities, and preparation for career advancement. SHAWNEE, Kan.--( BUSINESS WIRE )-- BioKansas , a life science nonprofit committed to preparing students for careers in the

PharmAbcine (KRX: 208340) (GM: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigationa

Medcolcanna Organics Inc. (“ Medcolcanna ”, “ MCCN ” or “the “ Company ”) (TSXV: MCCN), a leading Colombian and global integrated Cannabis Company, is pleased to provide an operational update and announce that it intends to proceed with a bridge debenture financing with the principal amount of $1,000,000 (the “ Offering ”). The Company intends to use the net proceeds from the financing for inventory production, inventory purchase, product ro

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance treatment in acrome